Metabasis Therapeutics Inc (MBRX1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Walter V. Klemp
Employees:
9
2575 WEST BELLFORT, SUITE 333, HOUSTON, TX 77054
713-300-5160

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company, which focuses on the development of anti-cancer drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms; and the metaboli® of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Data derived from most recent annual or quarterly report
Market Cap 10.902 Million Shares Outstanding35.168 Million Avg 30-day Volume 171.504 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.3
Price to Revenue0.0 Debt to Equity0.0 EBITDA-18.491 Million
Price to Book Value0.7001 Operating Margin0.0 Enterprise Value-15.235 Million
Current Ratio13.914 EPS Growth0.319 Quick Ratio13.675
1 Yr BETA 0.4139 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-18.0555 Altman Z-Score3.7285 Free Cash Flow to Firm -21.106 Million
View SEC Filings from MBRX1 instead.

View recent insider trading info

Funds Holding MBRX1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MBRX1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MPM BIOVENTURES II QP LP

MPM BIOVENTURES II LP

MPM BIOVENTURES GMBH & CO PARALLEL BETEILIGUNGS KG

MPM ASSET MANAGEMENT INVESTORS 2000B LLC

MPM ASSET MANAGEMENT II LP

MPM ASSET MANAGEMENT II LLC

GADICKE ANSBERT

STEINMETZ MICHAEL

WHEELER KURT

GALAKATOS NICHOLAS

  • 10% Owner
No longer subject to file 2010-01-27 0

EVNIN LUKE

  • Director
  • 10% Owner
No longer subject to file 2010-01-27 0

HALE DAVID F

  • Director
0 2009-06-23 0

ROHN WILLIAM R

  • Director
0 2009-06-23 0

ORONSKY ARNOLD L

  • Director
0 2009-06-23 0

BURGESS DANIEL D

  • Director
0 2009-06-23 0

LAIKIND PAUL K

  • Director
0 2009-06-23 0

SCHREINER GEORGE

  • Director
0 2009-06-23 0

STONER ELIZABETH

  • Director
0 2009-06-23 0

NGUYEN TRAN VP AND CFO

  • Officer
0 2009-03-02 0

BARACCHINI EDGARDO JR SR. VP OF BUSINESS DEVELOPMENT

  • Officer
0 2009-01-29 0

ERION MARK D CHIEF EXECUTIVE OFFICER

  • Officer
0 2009-01-29 0

MILLICAN TRISHA PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2009-01-29 0

GUMBINER BARRY VP CLINICAL DEVELOPMENT & CMO

  • Officer
0 2009-01-29 0

FOYT HOWARD VP OF CLINICAL DEVELOPMENT

  • Officer
0 2008-08-04 0

BECK JOHN W CHIEF FINANCIAL OFFICER

  • Officer
0 2008-04-02 0

CREDIT SUISSE/

  • 10% Owner
3,547,335 2006-11-03 0

GSCHWEND HEINZ W

  • Director
48,676 2006-06-07 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments